As of 2025-05-27, the Intrinsic Value of Parenteral Drugs (India) Ltd (PDPL.NS) is 42.80 INR. This PDPL.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 2.90 INR, the upside of Parenteral Drugs (India) Ltd is 1,375.70%.
The range of the Intrinsic Value is 21.59 - 92.91 INR
Based on its market price of 2.90 INR and our intrinsic valuation, Parenteral Drugs (India) Ltd (PDPL.NS) is undervalued by 1,375.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 21.59 - 92.91 | 42.80 | 1375.7% |
| DCF (Growth 10y) | 25.27 - 99.32 | 47.49 | 1537.4% |
| DCF (EBITDA 5y) | (7.56) - (4.26) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | 10.87 - 27.27 | 18.16 | 526.0% |
| Fair Value | -498.33 - -498.33 | -498.33 | -17,283.70% |
| P/E | (407.16) - (561.32) | (450.69) | -15641.2% |
| EV/EBITDA | 67.78 - 93.28 | 75.60 | 2506.8% |
| EPV | 2.96 - 45.03 | 24.00 | 727.5% |
| DDM - Stable | (20.70) - (48.06) | (34.38) | -1285.5% |
| DDM - Multi | (9.03) - (22.73) | (13.46) | -564.1% |
| Market Cap (mil) | 86.48 |
| Beta | 0.38 |
| Outstanding shares (mil) | 29.82 |
| Enterprise Value (mil) | 1,158.47 |
| Market risk premium | 8.31% |
| Cost of Equity | 67.78% |
| Cost of Debt | 11.78% |
| WACC | 13.05% |